Importantly, mice administered with IL-10-treated BM-DCs in a tolerance-inducing protocol, exhibited reduced allergic disease manifestations and Th2 responses that remained suppressed for up to 8 months [86]. This evidence concerns the gene IL10 and allergic disease.